摘要
目的 观察聚乙二醇干扰素α-2a联合利巴韦林治疗代偿期丙肝后肝硬化临床疗效.方法 21例慢性丙型肝炎后肝硬化患者（治疗组）,采用聚乙二醇干扰素α-2a 135～180 μ.g皮下注射,每周1次,利巴韦林片600～1000 mg/d,疗程48周,随访24周；20例慢性丙型肝炎患者（对照组）,聚乙二醇干扰素α-2a135～180 g皮下注射,每周1次,利巴韦林600～1000 mg/d,疗程48周,随访24周.比较两组快速病毒学应答（RVR）率、早期病毒学应答（EVR）率、持续病毒学应答（SVR）率,观察不良反应.结果 治疗组和对照组RVR、EVR、ETVR无显著性差异、治疗组SVR较对照组低（P＜0.05）,治疗组中骨髓抑制及贫血发生率更高（P＜0.05）,流感样症状,脱发,胃肠道反应等不良反应两组间差异无统计学意义.结论 丙肝后肝硬化患者,临床使用135 μg聚乙二醇干扰素α-2a及个体化、小剂量利巴韦林较为安全,可获得较好的早期应答,持续病毒学应答率较慢性肝炎为低,治疗过程应密切观察血常规及肝肾功能并处理不良反应.
Objective To study the clinical efficacy of PEG Interferon α-2a combined with ribavirin in treatment of with hepatitis C cirrhosis patients.Methods 21 patients with chronic hepatitis C cirrhosis （treated group）,were treated with peg-IFNα-2a 135 - 180 μg subcutaneously,i week,ribavirin tablets 800 -1000 mg/d,48 weeks of treatment and follow-up 24 weeks,20 patients with Chronic hepatitis C （control group）,were treated with peg-IFNα-2a 135 - 180 μg subcutaneously,1 week,ribavirin tablets 600 - 1000 mg/d,48 weeks of treatment,follow-up 24 weeks,comparison of rapid virological response （ RVR ） rates,early virologic response （EVR） rate,sustained virologic response （SVR） rate,adverse reactions was observed.Results The differences of RVR,EVR,ETVR in two groups is not significant,but SVR in treatment group was lower （ P 〈 0.05 ）,and has a higher incidence bone marrow suppression and anemia （ P 〈 0.05 ）.Flu-like symptoms,hair loss,gastrointestinal reactions and other adverse reactions was no significant difference between the two groups.Conclusion The use of 135 μg peg-IFNα-2a and individual in low-dose ribavirin hepatitis C patients with cirrhosis is more security,could get a good early response,but sustained virologic response （SVR） rates is lower than hepatitis C patients.Blood,liver and kidney function should be closely observed during treatment process.
出处
《中华实验和临床病毒学杂志》
CAS
CSCD
北大核心
2011年第6期477-479,共3页
Chinese Journal of Experimental and Clinical Virology
关键词
干扰素Α
肝硬化
利巴韦林
Interferon-alpha
Liver cirrhosis
Ribavirin
